Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:NVSEF, NYSE:MRK, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:BMY, NYSE:LLY, NYSE:JNJ, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Procter & Gamble, Pfizer Lead Market Gains 3 indexes reach new highs on Wednesday
U.S. market indexes continued to gain on Wednesday with all three leading indexes reaching new highs. Read more...
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Biosimilar for rheumatoid arthritis treatment demonstrated equivalent efficacy
Pfizer Inc. (NYSE:PFE) announced through the Business Wire on Jan. 5 that the results from a phase 3 study assessing the efficiency of PF-06410293, a biosimilar of AbbVie’s (NYSE:ABBV) Humira, in treating patients affected by rheumatoid arthritis met its primary endpoint. Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Which Criteria Best Determine the Success of Mergers? An evaluation of 3 recent mergers
Throughout the past three months, several mergers, including the $14 billion merger between Pfizer Inc. (NYSE:PFE) and Medivation Inc. (NASDAQ:MDVN), were announced. In part one of our study, we discussed how the John Paulson Merger Arb Checklist determines the success rate of mergers. This article will further the study by analyzing some of the recent mergers and predicting the success rate based on historical results. Read more...
Pfizer Acquires Medivation Company will pay $14 billion for biopharmaceutical business
Pfizer (NYSE:PFE) reported Monday that it would be acquiring, biopharmaceutical company, Medivation (NASDAQ:MDVN). Pfizer will pay $81.50 per share for a total value of approximately $14 billion. Shares of Medivation opened higher on Monday and gained approximately 20%. Read more...
Is Pfizer on Its Way Up? Patent expirations are countered by Hospira gains and organic growth
Pfizer (NYSE:PFE) finally had a good run this past six months. After what seemed to be an unstoppable slide in top line revenues, the company finally showed an impressive 15% increase to $26.2 billion from $22.7 billion in the year-ago six-month period. Unfortunately, the bottom line didn’t see much of that increase, and only went to $5.02 billion from $5 billion last year -- about 1% growth. Read more...
Pfizer Beats 2nd Quarter Revenue and Earnings Estimates Health care reporting good second-quarter results
Pfizer (NYSE:PFE) recently reported its second-quarter earnings with a revenue and earnings per share beat for the quarter. Pfizer is the final health care company in the Dow Jones Industrial Average to report earnings for the quarter. In the health care industry all four companies in the Dow Jones Industrial Average have beat revenue and earnings per share estimates for the quarter. Read more...
Gabelli Funds Comments on Pfizer Inc. Guru stock highlight
Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016. Read more...
Pfizer Investors Mood Dampened by Second Quarter Earnings Company’s guidance holds steady, but established drugs disappointed, pulling the stock downwards
Pharma major Pfizer (NYSE:PFE) raised its earnings guidance for 2016 after the first quarter results, increasing their 2016 revenue expectation to be in the range of $51 billion to $53 billion - a full two billion higher than their previous projection of $49 billion to $51 billion. After terminating its plan for a $150 billion mega-merger with Allergan (NYSE:AGN) earlier this year, Pfizer reported 11% revenue growth for the second quarter and 15% growth during the first half of this year compared to last year. These would seem to be solid numbers, but the stocks tell us a different story. Read more...
» More Articles for PFE

Ratios

vs
industry
vs
history
PE Ratio 30.83
PFE's PE Ratio is ranked lower than
54% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. PFE: 30.83 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.61  Med: 16.02 Max: 35.81
Current: 30.83
7.61
35.81
Forward PE Ratio 13.30
PFE's Forward PE Ratio is ranked higher than
64% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. PFE: 13.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.87
PFE's PE Ratio without NRI is ranked lower than
52% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. PFE: 30.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.25  Med: 18.91 Max: 35.44
Current: 30.87
11.25
35.44
Price-to-Owner-Earnings 25.77
PFE's Price-to-Owner-Earnings is ranked higher than
62% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. PFE: 25.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.93  Med: 11.54 Max: 36.68
Current: 25.77
5.93
36.68
PB Ratio 3.39
PFE's PB Ratio is ranked lower than
53% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. PFE: 3.39 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 2.38 Max: 3.7
Current: 3.39
1.28
3.7
PS Ratio 4.10
PFE's PS Ratio is ranked lower than
58% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. PFE: 4.10 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.79  Med: 3.49 Max: 5.43
Current: 4.1
1.79
5.43
Price-to-Free-Cash-Flow 25.43
PFE's Price-to-Free-Cash-Flow is ranked lower than
54% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. PFE: 25.43 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 12.91 Max: 25.81
Current: 25.43
5.92
25.81
Price-to-Operating-Cash-Flow 22.29
PFE's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. PFE: 22.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.45  Med: 11.52 Max: 22.62
Current: 22.29
5.45
22.62
EV-to-EBIT 22.77
PFE's EV-to-EBIT is ranked lower than
52% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. PFE: 22.77 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.7  Med: 14.2 Max: 29.6
Current: 22.77
7.7
29.6
EV-to-EBITDA 14.52
PFE's EV-to-EBITDA is ranked higher than
61% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. PFE: 14.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 17.7
Current: 14.52
5.6
17.7
PEG Ratio 14.62
PFE's PEG Ratio is ranked lower than
99.99% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. PFE: 14.62 )
Ranked among companies with meaningful PEG Ratio only.
PFE' s PEG Ratio Range Over the Past 10 Years
Min: 2.05  Med: 5.19 Max: 296.6
Current: 14.62
2.05
296.6
Shiller PE Ratio 27.57
PFE's Shiller PE Ratio is ranked higher than
80% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 47.37 vs. PFE: 27.57 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.92  Med: 14.85 Max: 28.01
Current: 27.57
8.92
28.01
Days Inventory 219.21
PFE's Days Inventory is ranked lower than
86% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. PFE: 219.21 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 102.61  Med: 226.68 Max: 355.66
Current: 219.21
102.61
355.66
Days Sales Outstanding 67.41
PFE's Days Sales Outstanding is ranked higher than
56% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. PFE: 67.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.09  Med: 71.29 Max: 106.89
Current: 67.41
61.09
106.89
Days Payable 102.04
PFE's Days Payable is ranked higher than
70% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. PFE: 102.04 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 108.56 Max: 179.46
Current: 102.04
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.56
PFE's Dividend Yield % is ranked higher than
87% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. PFE: 3.56 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.48  Med: 3.71 Max: 13.79
Current: 3.56
2.48
13.79
Dividend Payout Ratio 1.18
PFE's Dividend Payout Ratio is ranked lower than
72% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. PFE: 1.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.98
Current: 1.18
0.58
1.98
3-Year Dividend Growth Rate 20.80
PFE's 3-Year Dividend Growth Rate is ranked lower than
51% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. PFE: 20.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8.2 Max: 46.3
Current: 20.8
-33.8
46.3
Forward Dividend Yield % 3.76
PFE's Forward Dividend Yield % is ranked higher than
87% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. PFE: 3.76 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 7.51
PFE's 5-Year Yield-on-Cost % is ranked higher than
89% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. PFE: 7.51 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 5.23  Med: 7.83 Max: 29.09
Current: 7.51
5.23
29.09
3-Year Average Share Buyback Ratio 1.80
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. PFE: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -4 Max: 7.2
Current: 1.8
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.53
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. PFE: 1.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.01 Max: 1.91
Current: 1.53
0.62
1.91
Price-to-Median-PS-Value 1.10
PFE's Price-to-Median-PS-Value is ranked higher than
54% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. PFE: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.07 Max: 1.49
Current: 1.1
0.58
1.49
Earnings Yield (Greenblatt) % 4.37
PFE's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. PFE: 4.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 7.1 Max: 13.1
Current: 4.37
3.4
13.1
Forward Rate of Return (Yacktman) % 7.57
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
61% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. PFE: 7.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.57  Med: 57.8 Max: 111.9
Current: 7.57
7.57
111.9

More Statistics

Revenue (TTM) (Mil) $52,824
EPS (TTM) $ 1.16
Beta1.02
Short Percentage of Float0.55%
52-Week Range $28.74 - 37.39
Shares Outstanding (Mil)5,951.87

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 53,473 53,733 53,007
EPS ($) 2.58 2.79 2.74
EPS without NRI ($) 2.58 2.79 2.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.10%
Dividends per Share ($) 1.27 1.79 1.48
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Dow Jones Leads Market Gains on Thursday Feb 23 2017 
Why 3D Printing and Biotech Will Be Good Bets in 2017 Feb 23 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Procter & Gamble, Pfizer Lead Market Gains Feb 16 2017 
ANGEL Program Gets National Attention Feb 13 2017 
US Market Indexes Regain Some of Their Losses on Wednesday Feb 02 2017 
A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 
US Market Indexes Lower on Monday Jan 24 2017 

More From Other Websites
Details Still Missing on Republicans' 'Once in a Generation' Tax Plan Feb 24 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections Feb 24 2017
Pfizer’s Valuation after Its 4Q16 Earnings Release Feb 24 2017
1:10 pm Pfizer prices $1.065 bln aggregate principal amount of 4.20% notes due 2047 to professional... Feb 24 2017
Pfizer Prices $1,065,000,000 Debt Offering Feb 24 2017
Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; stable outlook Feb 24 2017
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs Feb 24 2017
Dow Jones Leads Market Gains on Thursday Feb 23 2017
United Therapeutics feels squeeze from increased pulmonary hypertension competition Feb 23 2017
PFIZER INC Files SEC form 8-K, Financial Statements and Exhibits Feb 23 2017
PFIZER INC Files SEC form 10-K, Annual Report Feb 23 2017
Dow logs 10th straight record, but Nasdaq stumbles a second day Feb 23 2017
Ronald E. Blaylock Elected to Pfizer’s Board of Directors Feb 23 2017
Johnson & Johnson, Pfizer Lead DJIA Higher on Thursday Feb 23 2017
Pfizer's Leukemia Candidate Gets Priority Review in U.S. Feb 22 2017
Pfizer Inc. (PFE) Invest For Attractive Valuation And The 4% Dividend Yield Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK